Douglas Williams

Douglas Williams

Directeur Général chez CODIAK BIOSCIENCES

Fortune : 10 929 $ au 30/06/2026

67 ans
Health Technology
Finance
Consumer Services

Profil

Douglas E.
Williams
is President & Chief Executive Officer at Codiak BioSciences, Inc. since 2015.
He is Chief Executive Officer at TriArm Therapeutics (Taiwan) Ltd. and Triarm Therapeutics Ltd. starting in 2024.
He serves as Chairman at Xenikos BV, Climb Bio, Inc. (since 2024), and CAMP4 Therapeutics Corp.
(starting 2025).
He is Director at eGenesis, Inc., Cygnal Therapeutics, Inc., Cytoimmune Therapeutics, Inc. (since 2021), Panacea Acquisition Corp.
II (since 2021), and Stablix, Inc. (since 2023).
Former roles include Chief Executive Officer & Director at ZymoGenetics, Inc. (2009–2010), Director, Chief Technology Officer & Executive VP at Immunex Corp.
(1988–2002), Director at Array BioPharma, Inc. (2004–2011), Director, Chief Scientific Officer, EVP-R&D at Seagen, Inc. (2002–2005), Director at Anadys Pharmaceuticals, Inc. (2004–2009), Independent Director at Ironwood Pharmaceuticals, Inc. (2014–2019), Director at Aerovance, Inc., Independent Director at Cascadian Therapeutics LLC (2011–2013), Independent Director at Ovid Therapeutics, Inc. (2016–2021), Independent Non-Executive Director at AC Immune SA (2018–2025), Director at Regulus Therapeutics, Inc. (2012–2017), Senior Vice President at Amgen, Inc. (2002–2003), Executive Vice President-Research & Development at Biogen, Inc. (2011–2015), Head-Health & Strategic Development at Genesis Research & Development Corp.
Ltd. (2002–2003), Executive Vice President at Biogen Idec New Ventures, Inc., Secretary & Trustee at Fred Hutchinson Cancer Research Center, and Executive VP, President-Research & Development at Sana Biotechnology, Inc. (2023–2024).
Education includes a doctorate from State University of New York at Buffalo, and undergraduate degrees from the University of Massachusetts Lowell and The Indiana University School of Medicine.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
10/06/2026 2 501 ( 0,01% ) 10 929 $ 30/06/2026
05/06/2026 0 ( -.--% ) - $ 30/06/2026

Postes actifs de Douglas Williams

SociétésPosteDébut
CODIAK BIOSCIENCES Directeur Général 01/08/2015
PANACEA ACQUISITION CORP. II Directeur/Membre du Conseil 06/04/2021
HUMORIGIN BIOTECHNOLOGY CORP Directeur Général 09/09/2024
CLIMB BIO, INC. Président 11/11/2024
CAMP4 THERAPEUTICS CORPORATION Président 10/09/2025
Directeur/Membre du Conseil -
Directeur Général 09/09/2024
Directeur/Membre du Conseil 18/01/2023
Directeur/Membre du Conseil 15/06/2021
░░░░░░░ ░░ ░░░░░░░░░░ -

Anciens postes connus de Douglas Williams

SociétésPosteFin
░░ ░░░░░░ ░░ ░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Douglas Williams

Formation de Douglas Williams

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

75

Relations au 1er degré

31

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées31

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Distribution Services

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Finance

Commercial Services

Health Technology

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Commercial Services

  1. Bourse
  2. Insiders
  3. Douglas Williams